Business Context and Reporting Period
This Form 8-K filing by Karyopharm Therapeutics Inc. reports on events occurring on January 24, 2018. The filing details the approval of stock option grants and compensation adjustments for key executive officers by the Board of Directors and the Compensation Committee.
Key Financial Metrics and Compensation Details
The filing does not report revenue, profit, cash flow, or debt metrics. It focuses exclusively on executive compensation.
Stock Option Grants
- Grant Date: January 24, 2018
- Exercise Price: $10.45 per share (Fair Market Value on grant date)
- Vesting Schedule: 25% on the first anniversary; remainder vests in equal increments over 36 months.
- Recipients and Share Counts:
- Michael G. Kauffman (CEO): 200,000 shares
- Sharon Shacham (President and CSO): 200,000 shares
- Christopher B. Primiano (EVP, CBO, GC, Secretary): 125,000 shares
- Michael F. Falvey (EVP, CFO, Treasurer): 95,000 shares
- Ran Frenkel (Chief Development Operations Officer): 60,000 shares
Salary and Bonus Adjustments
| Executive | 2017 Bonus | 2018 Annual Salary | 2018 Target Bonus % |
|---|---|---|---|
| Michael G. Kauffman (CEO) | $251,503 | $550,000 | 60% |
| Sharon Shacham (President/CSO) | $171,856 | $450,000 | 50% |
| Michael F. Falvey (EVP/CFO) | $46,135* | $404,000 | 40% |
| Christopher B. Primiano (EVP/CBO) | $163,770 | $404,000 | 40% |
| Ran Frenkel (CDO) | $95,208 | $341,000 | 40% |
* Amount prorated for the period from Mr. Falvey's hire date (September 11, 2017) through December 31, 2017.
Material Changes and Management Commentary
Promotion and Compensation Structure: Christopher B. Primiano received a larger option award (125,000 shares) to reflect his promotion to Executive Vice President, Chief Business Officer, General Counsel, and Secretary. This award was made in lieu of a larger promotional salary increase.
Effective Dates: New annual base salaries are effective January 1, 2018. Option grants are effective January 24, 2018.
Plan Authority: All options were granted pursuant to the Company's 2013 Stock Incentive Plan.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, risk factors, or contingencies beyond the standard vesting conditions of the stock options.
Key Facts for Investor Verification
- Verify the total dilution impact of the 680,000 new options granted to executives.
- Confirm the current stock price relative to the $10.45 exercise price to assess the intrinsic value of the grants.
- Note the significant increase in fixed salary costs for 2018 compared to 2017 bonus payouts.
- Review the vesting schedule to understand the retention timeline for key leadership (25% cliff vesting after one year).